Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Tools to Study Genomic Instability

AMSBIO has announced a new second generation PARP in vivo Pharmacodynamic Assay that accurately measures net poly (ADP-ribose) (PAR) levels in cellular extracts and has been used to document differences in PAR levels in human tumour lysates from a variety of tissues, organs and xenografts. 

Poly-ADP-ribose polymerase (PARP) is a protein involved in a number of cellular processes including catalysing the NAD-dependent addition of PAR onto itself and other adjacent nuclear proteins.  PARP-1 is widely regarded as a promising target for the development of drugs useful in various regimes of cancer therapy, inflammation, ischemia and neurodegeneration. More recently the discovery that breast cancers deficient in homologous recombination are sensitive to non-toxic PARP inhibitors has resulted in efforts by numerous pharmaceutical companies to develop PARP-1 specific drugs.

AMSBIO's PARP in vivo Pharmacodynamic Assay uses a validated sample processing regime and a chemiluminescent, sandwich ELISA format, with pre-coated 96-stripwell plates. The Assay reports PAR level with high signal to noise ratio; sensitivity of 2 pg/ml and a linear dynamic range to 1000 pg/ml.  Consequently the PARP in vivo Pharmacodynamic Assay offers an exciting new tool that provides evidence of drug action on  molecular targets and generates baseline values that may be used to stratify patient response to therapy.

Further information on the PARP in vivo Pharmacodynamic Assay is available at www.amsbio.com/parp-in-vivo-pharmacodynamic-assay.aspx or by contacting AMSBIO on tel. +44-1235-828200. For information detailing AMSBIO's complete range of PARP assay kits, enzymes and antibodies is available at www.amsbio.com/brochures/PAR_Bro_AMS.pdf.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized as a leading international provider of unique & innovative products & custom services for life sciences research. The amsbio range includes over 23,000 polyclonal & monoclonal antibodies, peptides, recombinant proteins, extracellular matrix, molecular detection reagents, & tissue DNA, RNA, protein & microarray products. Key research areas include: apoptosis, cell invasion & migration, cell signaling, DNA damage, electrophoresis, glycobiology, posttranslational modification & stem cell biology.


If you have not logged into the website then please enter your details below.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events